APOE ε3/ε4 and APOE ε4/ε4 were associated with higher odds of amyloid (CERAD‐ APOE ε3/ε4: OR = 3.75, 95% CI = 2.90 to 4.83, p < 0.001; APOE ε4/ε4: OR = 7.55, 95% CI = 4.16 to 13.69, p < 0.001) and tau accumulation (APOE ε3/ε4: OR = 1.78, 95% CI = 1.42 to 2.23, p < 0.001; APOE ε4/ε4: OR = 3.99, 95% CI = 2.25 to 7.08, p < 0.001), as well as AD neuropathological diagnosis (APOE ε3/ε4: OR = 3.07, 95% CI = 2.24 to 4.21, p < 0.001; APOE ε4/ε4: OR = 6.38, 95% CI = 3.11 to 13.08, p < 0.001) (Table S1). Here, MAPT is linked to Alzheimer disease.